Mutual inhibition through hybrid oligomer formation of daptomycin and the semisynthetic lipopeptide antibiotic CB-182,462

dc.contributor.authorZhang, TianHua
dc.contributor.authorMintzer, Evan
dc.contributor.authorTishbi, Nasim
dc.contributor.authorDesert, Celine
dc.contributor.authorSilverman, Jared
dc.contributor.authorTaylor, Scott D.
dc.contributor.authorPalmer, Michael
dc.date.accessioned2017-04-13T17:21:14Z
dc.date.available2017-04-13T17:21:14Z
dc.date.issued2013-02
dc.descriptionThe final publication is available at Elsevier via http://doi.org/10.1016/j.bbamem.2012.10.008 © 2013. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.description.abstractDaptomycin is a clinically important lipopeptide antibiotic that kills Gram-positive bacteria through membrane depolarization. Its activity requires calcium and the presence of phosphatidylglycerol in the target membrane. Calcium and phosphatidylglycerol also promote the formation of daptomycin oligomers, which have been assumed but not proven to be required for the bactericidal effect. Daptomycin shares substantial structural similarity with another lipopeptide antibiotic, A54145; the two have identical amino acid residues in 5 out of 13 positions and similar ones in 4 more positions. We here examined whether these conserved residues are sufficient for oligomer formation. To this end, we used fluorescence energy transfer and excimer fluorescence to detect hybrid oligomers of daptomycin and CB-182,462, a semisynthetic derivative of A54145. Mixtures of the two compounds indeed produced hybrid oligomers, but at the same time displayed a significantly less than additive antibacterial activity against Bacillus subtilis. The existence of functionally impaired oligomers indicates that oligomer formation is indeed important for antibacterial function. However, it also shows that oligomerization is not sufficient; once formed, the oligomers must take another step in order to acquire antibacterial activity. Thus, the amino acid residues shared between daptomycin and CB-182,462 suffice for formation of the oligomer, but not for its subsequent activation.en
dc.description.sponsorshipThis work was supported by a CHRP grant from NSERC and CIHR (M. Palmer and S. Taylor), by Yeshiva University (Evan Mintzer) and by a Henry Kressel scholarship (Nasim Tishbi).en
dc.identifier.urihttps://doi.org/10.1016/j.bbamem.2012.10.008
dc.identifier.urihttp://hdl.handle.net/10012/11661
dc.language.isoenen
dc.publisherElsevieren
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjecta54145en
dc.subjectBactericidal activityen
dc.subjectBindingen
dc.subjectCationic antimicrobial peptidesen
dc.subjectComplexen
dc.subjectDaptomycinen
dc.subjectFluorescenceen
dc.subjectInsertionen
dc.subjectIntermediateen
dc.subjectLipid-membranesen
dc.subjectLipopeptide antibioticsen
dc.subjectOligomerizationen
dc.subjectPore formationen
dc.subjectStaphylococcus-aureusen
dc.titleMutual inhibition through hybrid oligomer formation of daptomycin and the semisynthetic lipopeptide antibiotic CB-182,462en
dc.typeArticleen
dcterms.bibliographicCitationZhang, T., Muraih, J. K., Mintzer, E., Tishbi, N., Desert, C., Silverman, J., … Palmer, M. (2013). Mutual inhibition through hybrid oligomer formation of daptomycin and the semisynthetic lipopeptide antibiotic CB-182,462. Biochimica Et Biophysica Acta-Biomembranes, 1828(2), 302–308. https://doi.org/10.1016/j.bbamem.2012.10.008en
uws.contributor.affiliation1Faculty of Scienceen
uws.contributor.affiliation2Chemistryen
uws.peerReviewStatusRevieweden
uws.scholarLevelFacultyen
uws.typeOfResourceTexten

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
mutual-inhibition-2013-s.pdf
Size:
235.46 KB
Format:
Adobe Portable Document Format
Description:
Post-print

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
4.46 KB
Format:
Item-specific license agreed upon to submission
Description: